PFIZER emerge en los emergentes...(BRICS)

* Pfizer says emerging markets will be profitable

* Focus on China, Mexico, Turkey, Brazil, Russia, India

* Sees further acquisitions in emerging markets

"The psychology that emerging markets is not profitable is a myth," Jean-Michel Halfon, Pfizer's president of emerging markets, told a group of reporters at the company's New York headquarters .

Halfon said about 75 percent of pharmaceutical sales growth will come from emerging markets in the next 3 to 5 years, and the world's largest drugmaker aims to be a significant player.

He said Pfizer has had a presence in emerging markets for 50 years but is gearing up for a much bigger and broader push now, with an initial focus on the most promising of those markets: China, Mexico, Turkey, Brazil, Russia and India.

He also cited Saudi Arabia, Thailand and Taiwan as promising areas of interest.

Pfizer of course is not alone in its push, with most major pharmaceutical companies looking to China and other emerging markets as potential new sources of revenue.

Ver...

The drug giant expects to have about 3,200 sales representatives in about 250 Chinese cities by the end of 2011, up from about 2,300 sales reps in nearly 180 cities recently, Jean-Michel Halfon, president of Pfizer's emerging-markets business, told reporters at company headquarters here Tuesday.

"We are quite strong but we are a leader with a relatively small presence commercially" in China, Halfon said.

Halfon said China is expected to become the world's third-largest drug market by 2011, behind the U.S. and Japan, up from fifth recently.

Ver...